This study aimed to perform a prospective evaluation of 18F-NaF and 18F-FDG PET/CT in the detection of occult metastatic disease in men with prostate cancer and biochemical relapse.
Thirty-seven men with prostate-specific antigen (PSA) relapse (median, 3.2 ng/mL; range, 0.5–40.2 ng/mL) after definitive therapy for localized prostate cancer [26 radical prostatectomy (RP), 11 external beam radiation therapy] and negative conventional imaging underwent 18F-FDG and 18F-NaF PET/CT on 2 separate days within the same week. Studies were interpreted by 2 experienced radiologists in consensus for abnormal uptake suspicious for metastatic disease. The reference standard was a combination of imaging and clinical follow-up. Rank of PSA values for positive and negative PET/CT was compared using analysis of variance adjusting for primary therapy. Association between PSA and scan positivity in patients with RP was evaluated using Wilcoxon rank sum test.
Result of the 18F-FDG PET/CT scan was positive for nodal disease in 2 patients. True-positive detection rate for occult osseous metastases by 18F-NaF PET/CT was 16.2%. Median PSA levels for positive versus negative PET/CT scans were 4.4 and 2.9 ng/mL, respectively, with the difference marginally significant in prostatectomized men (P = 0.072). Percentages of patients with either 18F-NaF– or 18F-FDG–positive PET/CT in RP and external beam radiation therapy were 10% (n = 10) and undefined (n = 0) for a PSA of 2 ng/mL or less, 29% (n = 7) and 50% (n = 2) for PSA greater than 2 ng/mL but 4 ng/mL or less, 60% (n = 5) and 40% (n = 5) for PSA greater than 4 ng/mL but 10 ng/mL or less, and 25% (n = 4) and 25% (n = 4) for PSA greater than 10 ng/mL, respectively.
In biochemical relapse of prostate cancer, 18F-NaF PET/CT is useful in the detection of occult osseous metastases, whereas the yield of 18F-FDG PET/CT is relatively limited. 18F-NaF PET/CT positivity tends to associate with increasing PSA level in prostatectomized men and may occur in lower PSA ranges than conventionally recognized.
From the *Division of Nuclear Medicine, Department of Radiology, and †Department of Medicine, Division of Cancer Medicine, Kenneth J. Norris Jr. Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Received for publication February 10, 2012; revision accepted February 27, 2012.
This work was supported by the National Institutes of Health, National Cancer Institute Grant number R01-CA111613. The data collection and study management for this study were developed using CAFÉ (Common Application Framework Extensible) developed at University of Southern California’s Norris Comprehensive Cancer Center with support in part by award number P30CA014089 from the National Cancer Institute.
Conflicts of interest and sources of funding: none declared.
Reprints: Hossein Jadvar, MD, PhD, MPH, MBA, Keck School of Medicine of USC, University of Southern California, 2250 Alcazar St, CSC 102, Los Angeles, CA 90033. E-mail: email@example.com.